Lanean...
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve CLL p...
Gorde:
| Argitaratua izan da: | Cancers (Basel) |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6966427/ https://ncbi.nlm.nih.gov/pubmed/31766355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121834 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|